Steven Kosa, MD
Neurology · North Kansas City, MONPI 1700895083
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $275,705 of the $323,113 with a category attached, or 85.3%. 60 manufacturers reported payments, led by AbbVie at 35.7% of the total. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 815 payments — averaging $396.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$115K
- Lilly USA, LLC$56K
- Pfizer$25K
- Teva Pharmaceuticals USA, Inc.$23K
- Lundbeck LLC$20K
- Amgen$19K
- plus $63K from 54 others
Across 8 payments — averaging $6000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$37K
- H. Lundbeck A S$11K
What the payments were for
- Consulting fees$28,0599%
- Speaking & faculty fees$275,70585%
- Grants$440%
- Travel & lodging$4,2601%
- Food & beverage$14,8205%
- Education$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$323,113 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 191 | $229,525 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 54 | $223,597 |
| Kesimpta PenOfatumumab | 22 | $186,754 |
| Nurtec OdtRimegepant Sulfate | 133 | $181,754 |
| VumerityDiroximel Fumarate | 13 | $110,464 |
| UbrelvyUbrogepant | 62 | $100,440 |
| FingolimodFingolimod Hcl | 14 | $61,177 |
| BotoxOnabotulinumtoxina | 32 | $40,731 |
| Emgality PenGalcanezumab-Gnlm | 52 | $40,377 |
| BriviactBrivaracetam | 20 | $28,581 |
| ZavzpretZavegepant Hcl | 14 | $24,774 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $24,065 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $22,709 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $20,648 |
| ReyvowLasmiditan Succinate | 19 | $18,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Botox | $115,224 | $370,696285 claims |
| Grifols USA, LLCGamunex-C | $1,552 | $223,59754 claims |
| PfizerNurtec Odt, Zavzpret | $25,364 | $206,528147 claims |
| BiogenVumerity | $362 | $110,46413 claims |
| UCB, Inc.Briviact | $227 | $28,58120 claims |
| Lilly USA, LLCReyvow | $55,988 | $18,25319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 381 neurology providers in Missouri.
Other neurology in North Kansas City
- John EatmanNorth Kansas City$84K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
- Barbara GreenChesterfield$352K
- Seth HepnerBridgeton$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.